{"title":"达格列净治疗胶原纤维性肾小球病。","authors":"Enyu Imai, Atsuhiro Imai, Masaaki Izumi, Jun Nakazawa, Hideki Fujii, Shinichi Nishi","doi":"10.2169/internalmedicine.4952-24","DOIUrl":null,"url":null,"abstract":"<p><p>Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet been reported. A 45-year-old Japanese woman was treated daily with 10 mg dapagliflozin. Her eGFR slope improved from -3.61 mL/min/1.73 m<sup>2</sup>/year over 4 years before treatment to 0.11 mL/min/1.73 m<sup>2</sup>/year after 3 years of treatment. Additionally, her nephrotic-range proteinuria, initially exceeding 4 g/gCr, decreased to <2 g/gCr after dapagliflozin treatment. To our knowledge, this is the first documented case of effective treatment for collagenofibrotic glomerulopathy.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2615-2618"},"PeriodicalIF":1.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463412/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dapagliflozin for the Treatment of Collagenofibrotic Glomerulopathy.\",\"authors\":\"Enyu Imai, Atsuhiro Imai, Masaaki Izumi, Jun Nakazawa, Hideki Fujii, Shinichi Nishi\",\"doi\":\"10.2169/internalmedicine.4952-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet been reported. A 45-year-old Japanese woman was treated daily with 10 mg dapagliflozin. Her eGFR slope improved from -3.61 mL/min/1.73 m<sup>2</sup>/year over 4 years before treatment to 0.11 mL/min/1.73 m<sup>2</sup>/year after 3 years of treatment. Additionally, her nephrotic-range proteinuria, initially exceeding 4 g/gCr, decreased to <2 g/gCr after dapagliflozin treatment. To our knowledge, this is the first documented case of effective treatment for collagenofibrotic glomerulopathy.</p>\",\"PeriodicalId\":13719,\"journal\":{\"name\":\"Internal Medicine\",\"volume\":\" \",\"pages\":\"2615-2618\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463412/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.4952-24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4952-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Dapagliflozin for the Treatment of Collagenofibrotic Glomerulopathy.
Collagenofibrotic glomerulopathy is a rare, incurable kidney disease characterized by severe proteinuria and extensive type III collagen deposition in mesangial and subendothelial spaces. To date, no effective treatment has yet been reported. A 45-year-old Japanese woman was treated daily with 10 mg dapagliflozin. Her eGFR slope improved from -3.61 mL/min/1.73 m2/year over 4 years before treatment to 0.11 mL/min/1.73 m2/year after 3 years of treatment. Additionally, her nephrotic-range proteinuria, initially exceeding 4 g/gCr, decreased to <2 g/gCr after dapagliflozin treatment. To our knowledge, this is the first documented case of effective treatment for collagenofibrotic glomerulopathy.
期刊介绍：
Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine.
Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
